ECCO guidelines on therapeutics in Crohn's disease: medical treatment
…, P Bager, L Biancone, B Bokemeyer… - Journal of Crohn's …, 2020 - academic.oup.com
2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians. …
selected a panel of 48 experts supported by a team of methodologists and librarians. …
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations
G Van Assche, A Dignass, B Bokemeyer… - Journal of Crohn's …, 2013 - academic.oup.com
… Bernd Bokemeyer , Bernd Bokemeyer … Gert Van Assche, Axel Dignass, Bernd
Bokemeyer, Silvio Danese, Paolo Gionchetti, Gabriele Moser, Laurent Beaugerie, Fernando …
Bokemeyer, Silvio Danese, Paolo Gionchetti, Gabriele Moser, Laurent Beaugerie, Fernando …
ECCO guidelines on therapeutics in Crohn's disease: surgical treatment
…, P Bager, L Biancone, B Bokemeyer… - Journal of Crohn's …, 2020 - academic.oup.com
This article is the second in a series of two publications relating to the European Crohn’s
and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s …
and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s …
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease
…, P Marteau, T Iqbal, IL Khalif, J Stein, B Bokemeyer… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Iron deficiency anemia (IDA) is common in chronic diseases and
intravenous iron is an effective and recommended treatment. However, dose calculations and …
intravenous iron is an effective and recommended treatment. However, dose calculations and …
Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility
…, A Beecham, CN Bernstein, A Bitton, B Bokemeyer… - Nature …, 2022 - nature.com
Genome-wide association studies (GWASs) have identified hundreds of loci associated with
Crohn’s disease (CD). However, as with all complex diseases, robust identification of the …
Crohn’s disease (CD). However, as with all complex diseases, robust identification of the …
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis
AU Dignass, B Bokemeyer, H Adamek, M Mross… - Clinical …, 2009 - Elsevier
BACKGROUND & AIMS: Oral mesalamine (5-aminosalicylate) is the current standard of care
for mild-to-moderate ulcerative colitis. We investigated the efficacy and safety of once daily …
for mild-to-moderate ulcerative colitis. We investigated the efficacy and safety of once daily …
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 …
…, M Blaeker, S Bloom, B Bokemeyer… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous
phase 2 induction study, etrolizumab significantly improved clinical remission versus …
phase 2 induction study, etrolizumab significantly improved clinical remission versus …
Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program
…, Z Tulassay, DC Baumgart, B Bokemeyer… - Inflammatory bowel …, 2015 - academic.oup.com
Background Iron deficiency anemia (IDA) is frequently seen in inflammatory bowel disease.
Traditionally, oral iron supplementation is linked to extensive gastrointestinal side effects …
Traditionally, oral iron supplementation is linked to extensive gastrointestinal side effects …
Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases—a prospective study on incidence and severity
N Teich, W Mohl, B Bokemeyer… - Journal of Crohn's …, 2016 - academic.oup.com
Background and Aims: Azathioprine [AZA] is recommended for maintenance of steroid-free
remission in inflammatory bowel disease IBD. The aim of this study has been to establish the …
remission in inflammatory bowel disease IBD. The aim of this study has been to establish the …
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease
R Evstatiev, O Alexeeva, B Bokemeyer, I Chopey… - Clinical …, 2013 - Elsevier
BACKGROUND & AIMS: Iron-deficiency anemia is the most common systemic complication
of inflammatory bowel diseases (IBD). Iron-deficiency anemia recurs frequently and rapidly …
of inflammatory bowel diseases (IBD). Iron-deficiency anemia recurs frequently and rapidly …